Envisia genomic classifier for suspected idiopathic pulmonary fibrosis
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - Rhode Island policy alerts
Know when Blue Cross Blue Shield - Rhode Island releases new policies or updates existing guidance.
Monitor payer policy activity
Policy governing coverage and prior authorization requirements for the Envisia Genomic Classifier (Veracyte) for patients with interstitial lung disease suspected of idiopathic pulmonary fibrosis when HRCT is not definitive; applies to Medicare Advantage and commercial products under BCBSRI.
No material clinical or coverage changes in this revision.
Coverage criteria for Envisia Genomic Classifier
Envisia should not be used when a definitive radiographic diagnosis can already be established or when the test result would not change diagnostic confidence. Examples include: a typical UIP pattern on HRCT, HRCT showing features most consistent with a non‑IPF diagnosis, or situations where a positive Envisia result is unlikely to lead to a confident diagnosis of IPF (i.e., >90% confidence).
Coverage and payment for Envisia are subject to the member’s specific benefit documents (subscriber agreement, member certificate, and/or employer agreement). These plan documents govern benefit determination and supersede this medical policy; providers must verify member eligibility and benefits with the provider call center prior to testing.
Envisia is unlikely to provide clinical benefit when the pre‑test likelihood of histologic UIP exceeds 90%. Examples include a Probable UIP HRCT pattern in an adult >70 years with extensive reticulation (>1/3 of lung fields), and a Probable UIP pattern in men >50 years or women >60 years with moderate‑to‑severe traction bronchiectasis.
If services are determined to be not medically necessary or are non‑covered under the member’s benefit plan, providers may not bill or charge the member for those services unless the member has been informed and has provided written agreement in advance to assume financial responsibility.
Coding and billing
| 81554 | Pulmonary disease (idiopathic pulmonary fibrosis [IPF]), mRNA, gene expression analysis of 190 genes, utilizing transbronchial biopsies, diagnostic algorithm reported as categorical result (eg, positive or negative for high probability of usual interstitial pneumonia [UIP]) |
Provider actions, prior authorization and billing responsibilities
Prior Authorization Required
Prior authorization is required for CPT 81554 (Envisia Genomic Classifier). Obtain prior authorization from Blue Cross Blue Shield - Rhode Island before ordering the test. Laboratories or their representatives are not permitted to obtain authorization on behalf of the ordering physician; only the ordering physician may participate in the prior authorization, appeal, or medical necessity processes.
- Prior authorization required for CPT 81554
Prior authorization / benefit verification
Verify member-specific benefits and eligibility with BCBSRI before ordering the Envisia Genomic Classifier. Coverage is determined by the member’s subscriber agreement, certificate, or employer agreement and may vary by product (Medicare Advantage vs Commercial). Contact the provider call center for member-specific information.
- Verify benefits and prior authorization prior to testing
- Coverage may differ by product
Required documentation to support prior authorization
Provide documentation to support medical necessity when submitting a prior authorization request. Documentation should demonstrate the patient is eligible for bronchoscopy with transbronchial biopsies, include chest HRCT findings (Probable UIP or Indeterminate for UIP), exclusion of autoimmune disease when appropriate, and absence of definitive occupational/environmental/medication-related cause.
- Document bronchoscopy eligibility and transbronchial biopsy status
- Include HRCT results showing Probable UIP or Indeterminate for UIP
- Document evaluation excluding autoimmune, occupational, environmental, or medication causes
Unauthorized service billing denied
Do not bill members for services that are denied for lack of prior authorization, not medically necessary, or are non-covered benefits unless the member was informed in advance and agreed in writing to accept financial responsibility. If a laboratory provides a service that was not authorized, the service will be denied and the financial liability rests with the participating laboratory and may not be billed to the member.
- Services without required authorization will be denied and cannot be billed to the member
- Members may only be billed if informed in advance and they provided written agreement
Denial and member financial liability
If services are determined to be not medically necessary or are non-covered under the member’s plan, they may be denied and cannot be charged to the member unless the member provided prior written consent to pay. Providers should review the member’s benefit documents and participation agreement for applicable provisions and consult the provider call center for questions.
- Denials for lack of medical necessity or non-covered services may not be billed to the member without prior written agreement
- Review member-specific coverage and participation agreement terms
Provider action (operational details)
Preserve for content writer: provider action specifics (operational steps, contact numbers, internal forms) to be populated.
Provider action (appeals / benefit verification)
Preserve for content writer: additional provider action callout (e.g., appeals workflow, documentation templates) to be populated.
Background on the Envisia test and clinical context
Envisia is a tissue‑based, multianalyte mRNA genomic classifier performed on transbronchial biopsy specimens to yield a categorical result (for example, UIP or Non‑UIP). It is intended to assist diagnosis of usual interstitial pneumonia in patients with suspected idiopathic pulmonary fibrosis when HRCT is not definitive, potentially avoiding the need for surgical lung biopsy.
Definitions and diagnostic radiology patterns
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.